Skip to main navigation Skip to search Skip to main content

A nocturnal temperature controlled laminar flow device (TLA) maintains good control of severe allergic asthma (SAA) after withdrawal of Omalizumab therapy

Research output: Contribution to journalJournal Article peer-review

Original languageAmerican English
JournalEuropean Respiratory Journal
Volume52
DOIs
StatePublished - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this